

# ADVANCE PROGRAM



## HFSA Virtual Board Certification Review 2021

*Advanced Heart Failure & Transplant Cardiology*



Visit [hfsa.org/boardreview2021](https://hfsa.org/boardreview2021) to learn more.



## ABOUT THE COURSE

The HFSA Virtual Board Certification Review 2021 content is based on the ABIM content blueprint for the certification examination in Advanced Heart Failure and Transplant Cardiology. It will be held over the course of 3 days (July 16-18, 2021) and include pre-recorded ondemand webinars.

This activity will use concise didactic presentations by national experts, case studies, and panel discussions. An audience response system (ARS) will be utilized throughout all presentations in designated session time. Additional question and answer periods with faculty will enabling attendees to drive the discussion of according to their most pressing clinical challenges.

Registered attendees will receive a reading list that contains additional references regarding guidelines- and evidence-based therapy, and a question bank to help prepare for the examination.

The following areas are addressed:

- Epidemiology and Causes of Heart Failure
- Pathophysiology of Heart Failure
- Evaluation of Heart Failure
- Management of Hospitalized Patients
- Management of Heart Failure
- Comorbidities or Coexisting Conditions
- Cardiac Surgery in Heart Failure
- Heart Transplant
- Mechanical Circulatory Support
- Pulmonary Arterial Hypertension
- Contemporary HF Management Topics

The program will be made up of the following components to allow attendees greater access to the content.

## ABIM AHFTC CERTIFICATION DATES

### ABIM AHFTC Maintenance of Certification Exam Date:

MOC EXAM DATE OPTIONS	REGISTRATION DATES
<b>Fall 2021:</b> Oct. 14, 2021	Dec. 1, 2020 through Aug. 15, 2021
<b>Fall 2022:</b> Nov. 1, 2022	Dec. 1, 2021 through Aug. 15, 2022

### ABIM AHFTC Certification Exam Date:

CERTIFICATION DATE OPTIONS	REGISTRATION DATES
<b>Fall 2022:</b> Nov. 1, 2022	Dec. 1, 2021 through June 15, 2022

Visit [www.abim.org](http://www.abim.org) for additional information about the certification exam.

## PROGRAM COMPONENTS

### ONDEMAND WEBINAR SERIES: HEART FAILURE FUNDAMENTALS

Available in early July, this pre-recorded, ondemand webinar series features the basics and can be completed at the attendee's convenience.

### VIRTUAL MEETING DATES (July 16-18, 2021)

Three virtual meeting dates (July 16-18, 2021) delivered by top experts in the field. Attendees should anticipate being online throughout to receive maximum value from these sessions. If a session must be missed due to other circumstances, all sessions will be available for attendees to download and access approximately 24-48 after the session date. Full agenda is available at [hfsa.org/boardreview2021/program](http://hfsa.org/boardreview2021/program).

### FACULTY "OFFICE HOURS"

Post-meeting, virtual livestream Q&A panel taking place in early October to allow attendees to ask last-minute questions prior to the examination in October.

### ADDITIONAL BONUS FEATURES

In addition to the core program components, attendees will have access to the following:

- A question bank
- Recommended reading list
- Live polling, Q&A, and chat features available during the virtual meeting days
- Chat with fellow attendees and faculty throughout the course of the meeting





## ABIM CERTIFICATION DEADLINES

This HFSA Virtual Board Certification Review 2021 has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

## CREDIT DESIGNATION



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

This HFSA Virtual Board Certification Review has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

### Physicians

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The Heart Failure Society of America designates this educational activity for a maximum of *20.50 AMA PRA Category 1 Credits™*.

The Heart Failure Society of America designates this live activity for a maximum of *20.50 AMA PRA Category 1 Credits™*. Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 20.50 MOC points in the Maintenance of Certification (MOC) program.

Learners should claim only the credit commensurate with the extent of their participation in the activity.

## LEARNING OBJECTIVES

Upon completion of the activity, participants will demonstrate improved competence and ability to:

### For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:

1. Identify gaps in knowledge about advanced heart failure and transplant cardiology
2. Focus study efforts on filling identified knowledge gaps
3. Practice for the certification examination with ABIM-style multiple-choice test questions

### For Clinical Practice:

1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
3. Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
5. Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
8. Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device

Concise presentations by national experts will focus on blueprint content.





## FACULTY (FACULTY SUBJECT TO CHANGE)

### CO-CHAIRS

#### **Akshay S. Desai, MD, MPH, FHSA**

Medical Director, Cardiomyopathy and Heart Failure Program,  
Advanced Heart Disease Section  
Brigham and Women's Hospital  
Boston, MA

#### **Maria Rosa Costanzo, MD**

Medical Director, Heart Failure Research, Advocate Heart Institute  
Medical Director, Edward Hospital Center for Advanced Heart Failure  
Naperville, IL

#### **Jonathan Rich, MD, FHSA**

Associate Professor of Medicine  
Northwestern University, Feinberg School of Medicine  
Medical Director, Mechanical Circulatory Support Program  
Program Director, Advanced Heart Failure and Transplant Fellowship  
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital  
Chicago, IL

#### **Nancy Sweitzer, MD, PhD, FHSA**

Professor of Medicine  
Chief of Cardiology  
Director, Sarver Heart Center  
University of Arizona  
Tucson, AZ

#### **Daniel Burkhoff, MD, PhD**

Columbia University  
New York, NY

#### **Brian Claggett, PhD**

Chief Statistician, Cardiac Imaging Core Laboratory and Clinical  
Trials Endpoints Center  
Brigham and Women's Hospital  
Assistant Professor  
Harvard Medical School  
Boston, MA

#### **Jennifer Cowger, MD, MS**

Medical Director of Mechanical Circulatory Support Program  
Co-Director of the Cardiac Intensive Care Unit  
Henry Ford Hospitals, Detroit Michigan  
Associate Professor, Wayne State University  
Detroit, MI

#### **Mark Drazner, MD, MSc, FHSA**

Clinical Chief of Cardiology  
Medical Director of the LVAD and Cardiac Transplantation Program  
Professor  
University of Texas Southwestern Medical Center  
Dallas, TX

#### **James Fang, MD, FHSA**

Professor of Medicine  
Chief, Division of Cardiovascular Medicine  
Executive Director, Cardiovascular Service Line  
University of Utah  
Salt Lake City, UT

#### **Sadiya Khan, MD, MSc**

Associate Professor of Medicine – Cardiology  
Associate Professor of Preventive Medicine – Epidemiology  
Northwestern University Feinberg School of Medicine  
Chicago, IL

#### **Michelle Kittleson, MD, PHD**

Professor of Medicine  
Director of Post Graduate Medical Education in Heart Failure  
and Transplantation  
Director of Heart Failure Research  
Cedars Sinai Medical Center  
Beverly Hills, CA

#### **Eric Krieger, MD**

Associate Professor of Medicine  
Director, Seattle Adult Congenital Heart Service  
Director, Adult Congenital Heart Disease Fellowship  
Attending Physician, University of Washington Medical Center  
University of Washington School of Medicine  
Seattle Children's Hospital  
Seattle, WA

#### **Bonnie Ky, MD, MSCE**

Assistant Professor of Medicine  
University of Philadelphia  
Philadelphia, PA

#### **Gregory Lewis, MD**

Section Head, Heart Failure  
Director, Cardiopulmonary Exercise Testing Laboratory  
Medical Director, Cardiac Transplantation Program  
Massachusetts General Hospital  
Boston, MA





## FACULTY (CONTINUED)

**Jon Lomasney, MD**

Associate Professor of Pathology  
Associate Professor of Pharmacology  
Feinberg School of Medicine of Northwestern University  
Chicago, IL

**Sean Pinney, MD**

Co-Director of the Heart & Vascular Center  
Director of Heart Failure & Transplantation and Director of  
Clinical & Translational Research  
Director, Advanced Heart Failure and Transplantation  
Program  
University of Chicago, Chicago, IL

**Joseph Rogers, MD**

President and CEO  
Texas Heart Institute  
Houston, TX

**Sanjiv Shah, MD**

Stone Professor of Medicine  
Director of Research, Bluhm Cardiovascular Institute  
Director, Northwestern HFpEF Program  
Division of Cardiology, Department of Medicine  
Northwestern University Feinberg School of Medicine  
Chicago, IL

**Jeffrey Testani, MD, MTR**

Associate Professor of Medicine  
Director of Heart Failure Research, Cardiovascular Medicine  
Co-Director Heart & Vascular Center Clinical Research, Heart &  
Vascular Center  
Yale Heart and Vascular Center  
New Haven, CT

**Roderick Tung, MD**

Professor of Medicine  
Director, Cardiac Electrophysiology & EP Laboratories  
The University of Chicago Medicine  
Chicago, IL

**Wendy Tzou, MD**

Associate Professor of Medicine  
Director, Cardiac Electrophysiology  
University of Colorado  
Aurora, CO

**Jane Wilcox, MD, MSc, FHSA**

Assistant Professor of Medicine-Cardiology  
Director, Myocardial Recovery Program  
Northwestern University Feinberg School of Medicine  
Chicago, IL

**Clyde W. Yancy, MD, MSc, FHSA**

Vice Dean, Diversity & Inclusion  
Magerstadt Professor of Medicine  
Professor, Medical Social Sciences  
Chief, Division of Cardiology  
Northwestern University Feinberg School of Medicine  
Chicago, IL

*Note: Faculty is subject to change and will be updated continuously up to the conference.*





## HFSA VIRTUAL BOARD REVIEW 2021

- OnDemand Webinar Series: Heart Failure Fundamentals
- HFSA Virtual Board Certification Review 2021 - July 16-18, 2021
  - » Day 1 | July 16 | 3:00 PM – 6:20 PM ET
  - » Day 2 | July 17 | 11:00 AM - 8:00 PM ET
  - » Day 3 | July 18 | 11:00 AM – 5:30 PM ET
- Faculty “Office Hours” Virtual Live-Stream Panel – October 2021 (TBD)

### OnDemand Webinar Series: Heart Failure Fundamentals

			PRESENTATION	SPEAKER(S)
			Heart Failure Epidemiology and Risk Factors	Sadiya Khan
			Pathophysiology I: Cellular and Energetic Considerations	Daniel Burkhoff
			Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations	Daniel Burkhoff
			Diagnosis and Clinical Assessment	Mark Drazner
			Cardio-Oncology for the HF boards	Bonnie Ky
			Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards	Jon Lomasney
			Statistics for the HF Board	Brian Claggett

### DAY 1 - JULY 16, 2021

**3 PM - 6:20 PM EST**

ET Time	CT Time	PT Time	PRESENTATION	SPEAKER(S)
3:00 PM	2:00 PM	12:00 PM	Welcome & HFSA Introduction	Akshay Desai, John Barnes
<b>SESSION I: Cardiac Transplant</b>				
3:20 PM	2:20 PM	12:20 PM	Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies	Nancy Sweitzer
3:50 PM	2:50 PM	12:50 PM	Immunology: The Basics, PRA, Sensitization, Crossmatch	Sean Pinney
4:20 PM	3:20 PM	1:20 PM	Rejection: Cellular and Antibody Mediated	Sean Pinney
4:50 PM	3:50 PM	1:50 PM	Managing Immunosuppression and Drugs	Michelle Kittleson
5:20 PM	4:20 PM	2:20 PM	Heart Transplant, Clinical Outcomes and Complications	Michelle Kittleson
<b>Q&amp;A Panel I</b>				
5:50 PM	4:50 PM	2:50 PM	Q&A Panel 1	Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer
6:20 PM	5:20 PM	3:20 PM	<b>Day 1 Adjourns</b>	





## HFSA VIRTUAL BOARD REVIEW 2021 (CONTINUED)

**DAY 2 - JULY 17, 2021**

**11 AM - 8 PM EST**

ET Time	CT Time	PT Time	PRESENTATION	SPEAKER(S)
11:00 AM	10:00 AM	8:00 AM	Welcome & Introductions	Akshay Desai
<b>SESSION II: Key Issues in HF Management</b>				<b>Moderator: Jonathan Rich</b>
11:15 AM	10:15 AM	8:15 AM	Hemodynamics in HF I	James Fang
11:45 PM	10:45 AM	8:45 AM	Hemodynamics in HF II	James Fang
12:15 PM	11:15 AM	9:15 AM	Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)	Clyde Yancy
12:45 PM	11:45 PM	9:45 AM	Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)	Mark Drazner
1:15 PM	12:15 PM	10:15 AM	<b>BREAK</b>	
1:45 PM	12:45 PM	10:45 AM	HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)	Sanjiv Shah
2:15 PM	1:15 PM	11:15 AM	Pulmonary Hypertension	Jonathan Rich
2:45 PM	1:45 PM	11:45 AM	Management of Common Arrhythmias I - Atrial Fib and Flutter	Roderick Tung
3:15 PM	2:15 PM	12:15 PM	Management of Common Arrhythmias in HF II	Roderick Tung
3:45 PM	1:45 PM	11:45 AM	Device Therapy in Heart Failure I - Sudden Death Prevention	Wendy Tzou
4:15 PM	3:15 PM	1:15 PM	Device Therapy in Heart Failure II - CRT	Wendy Tzou
4:45 PM	3:45 PM	2:45 PM	<b>BREAK</b>	
5:00 PM	4:00 PM	2:00 PM	Management of the Hospitalized HF Patient	Maria Rosa Costanzo
5:30 PM	4:30 PM	2:30 AM	Cardio Renal Failure Interactions in Heart Failure	Jeff Testani
<b>SESSION III: Specific Heart Failure Syndromes</b>				<b>Moderator: Jonathan Rich</b>
6:00 PM	5:00 PM	3:00 PM	Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)	Akshay Desai
6:30 PM	5:30 PM	3:30 PM	Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)	Jane Wilcox
7:00 PM	6:00 PM	4:00 PM	Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)	Sanjiv Shah
<b>Q&amp;A Panel II</b>				
7:30 PM	6:30 PM	4:30 PM	Q&A Panel II	Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer
8:00 PM	7:00 PM	5:00 PM	<b>Day 2 Adjourns</b>	





## HFSA VIRTUAL BOARD REVIEW 2021 (CONTINUED)

**DAY 3 - JULY 18, 2021**

**11:00 AM - 5:30 PM EST**

ET Time	CT Time	PT Time	PRESENTATION	SPEAKER(S)
11:00 AM	10:00 AM	8:00 AM	Welcome & Introductions	Akshay Desai
<b>SESSION IV - Shock/MCS</b>				<b>Modertator: Nancy Sweitzer</b>
11:15 AM	10:15 AM	8:15 AM	Cardiogenic Shock Management	Nancy Sweitzer
11:45 AM	10:45 AM	8:45 AM	MCS I: Durable MCS Devices and Outcomes	Joseph Rogers
12:15 PM	11:15 AM	9:15 AM	MCS II: Temporary Support Devices and ECMO for the Boards	Jennifer Cowger
12:45 PM	11:45 AM	8:45 AM	MCS III: MCS Complications and Patient Management	Jennifer Cowger
1:15 PM	12:15 PM	10:15 AM	MCS IV: Interactive Shock and Device Management	Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer
2:15 PM	1:15 PM	11:15 AM	<b>BREAK</b>	
<b>SESSION V: Special Topics in HF</b>				<b>Moderator: Akshay Desai</b>
2:30 PM	1:30 PM	11:30 AM	Assessment of Functional Capacity including cardiopulmonary exercise testing	Gregory Lewis
3:00 PM	2:00 PM	12:00 PM	Adult Congenital Heart Disease for the HF Specialist	Eric Krieger
3:30 PM	2:30 PM	12:30 PM	Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)	Akshay Desai
4:00 PM	3:00 PM	1:00 PM	Management of Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS, tricuspid regurgitation)	Jane Wilcox
4:30 PM	3:30 PM	1:30 PM	Management of Comorbidities in Heart Failure - Diabetes, Sleep Disorders, Iron Deficiency/Anemia, COPD	Maria Rosa Costanzo
<b>Q&amp;A Panel III</b>				
5:00 PM	4:00 PM	2:00 PM	Q&A Panel III	Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer
5:30 PM	4:30 PM	2:30 PM	<b>Day 3 Adjourns</b>	

### FACULTY OFFICE HOURS

**(October 2021 - Date TBD)**

ET Time	CT Time	PT Time	TALK TITLE	SPEAKER
TBD	TBD	TBD	Faculty Office Hours	Akshay Desai, Maria Rosa Costanzo, Jonathan Rich, Nancy Sweitzer







9211 Corporate Blvd, Suite 270  
Rockville, MD 20850

T: (301) 798-4493 | F: (301) 798-7794 | [www.hfsa.org](http://www.hfsa.org)

Visit [hfsa.org/boardreview2021](http://hfsa.org/boardreview2021) to learn more.